Veracyte, Inc.
VCYT
Rang in aandelen
#4238
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Aandeelprijs
$45.89
Marktkapitalisatie
$3.69B
Verandering (1 dag)
-0.70%
Verandering (1 jaar)
32.07%
Land
US
Handel Veracyte, Inc. (VCYT)
Categorie
Healthcare
Koersgeschiedenis voor Veracyte, Inc. (VCYT)
Hoogste slotkoers: $44.59 op 2026-10-01
Laagste slotkoers: $12.82 op 2013-10-01
Laagste slotkoers: $12.82 op 2013-10-01
Koersgeschiedenis van Veracyte, Inc. van 2013 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | -2.87% |
| 2025 | 3.85% |
| 2024 | 55.02% |
| 2023 | 1.26% |
| 2022 | -33.63% |
| 2021 | -25.42% |
| 2020 | 88.25% |
| 2019 | 137.21% |
| 2018 | 87.23% |
| 2017 | -13.42% |
| 2016 | 5.54% |
| 2015 | -8.13% |
| 2014 | -43.76% |
| 2013 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $687.28 | 21.17% |
US
|
|
| $233.21 | 6.93% |
US
|
|
| $400.73 | 113.13% |
US
|
|
| $21.16 | 49.45% |
CN
|
|
| $175.78 | 20.50% |
US
|
